Human coagulation factor VII (FVII) is a vitamin K-dependent glycoprotein that plays an important role in the blood coagulation process, being one of the key molecules involved in blood clot formation. Currently, the commercial product is produced in a murine cell line, BHK-21, which gives disadvantages considering the complexity of post-translational modifications of this protein. Murine cells simply do not possess the "machinery" required for human-type glycosylation. These differences in glycosylation pattern may be highly immunogenic in humans, and/or may be rapidly cleared the recombinant protein from circulation. Nevertheless, bioprocesses for recombinant protein production using mammalian cells have now focused on the use of serum-free suspension cultures. Based on this, the aim of this project is to express the coagulation factor VII (FVII) in a human Hek293 cell line adapted to serum-free suspension culture by stable and transient transfection. The technology learned during this project will be applied to the cells that are being used in the doctoral project.
News published in Agência FAPESP Newsletter about the scholarship: